Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02627196 · ClinicalTrials.gov registry record · NA
Baroreflex Activation Therapy for Heart Failure
A NA study, sponsored by CVRx.
- Completed
- Registry status
- NA
- Development phase
- 1,090
- Enrollment target
NCT02627196: Completed NA study, sponsored by CVRx.
NCT02627196 is a NA study that has completed, run by CVRx. The registered enrollment target is 1,090 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02627196, a NA study, has completed, sponsored by CVRx.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,090 participants
- Enrollment target
Study Summary
The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP\<1600 pg/ml despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT). The total trial duration is anticipated to be approximately 5 years; however, the duration of an individual subject enrollment will depend on when he or she entered the trial.
Interventions
- DRUG Medical Management
- DEVICE BAROSTIM NEO® System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,090 participants |
| Start Date | 2016-04-19 |
| Est. Completion | 2023-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02627196
The ClinicalTrials.gov registry entry for NCT02627196 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,090 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CVRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medical Management is the first listed.
NCT02627196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02627196 about?
NCT02627196 is a clinical study titled "Baroreflex Activation Therapy for Heart Failure". The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejec...
What is the current status of trial NCT02627196?
This trial is currently completed. It is a NA study. The enrollment target is 1,090 participants. The study started on 2016-04-19. Estimated completion is 2023-10.
What interventions are being tested in trial NCT02627196?
The interventions under investigation include: Medical Management (DRUG), BAROSTIM NEO® System (DEVICE).
Who is sponsoring clinical trial NCT02627196?
This trial is sponsored by CVRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.